Published Date: 31-Mar-2022
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Non-invasive Aesthetic Treatment Market size is expected to reach $116.4 billion by 2027, rising at a market growth of 13.9% CAGR during the forecast period.
The Hospital/Surgery Center has shown high growth rate of 14.1% during (2021 - 2027). This is due the better healthcare facilities which are equipped with advanced tools & techniques for the treatments. Furthermore, the high demand of non-invasive aesthetic treatments in hospitals is because of the trust people have on hospitals and surgery centers.
The Injectables segment acquired the maximum revenue share in the Global Non-invasive Aesthetic Treatment Market by Procedure 2020, thereby, achieving a market value of $73.4 billion by 2027. The injectable is easy to use for surgeons and have faster results due to which the clients prefer to have injectable for skin treatments resulting in the high demand if them. New-generation aesthetic procedures & products are rapidly expanding with a wide range of variety leading to increasing demand for injectable into demographic groups.
The North America is the fastest growing region in the Global Non-invasive Aesthetic Treatment Market by Region 2020, thereby, achieving a market value of $42.2 billion by 2027. The Europe market is estimated to witness a CAGR of 14.2% during (2021 - 2027). Additionally, The Asia Pacific market would experience a CAGR of 14.4% during (2021 - 2027).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Alma Lasers Ltd., Allergan PLC, Galderma S.A., Merz Pharma GmbH & Co. KGaA, Johnson & Johnson, Candela Medical Corporation, Bausch Health Companies, Inc., Cutera, Inc., Lumenis Ltd., and Hologic, Inc.
Unique Offerings from KBV Research